• Failure-free survival is a potentially useful, efficient, and robust basis for interpreting results of initial treatment of chronic GVHD.
Introduction
Chronic graft-versus-host disease (GVHD) occurs in 30% to 50% of patients after allogeneic hematopoietic cell transplantation. 1, 2 This complication causes significant late morbidity and mortality and prolongs the duration of immunosuppressive treatment (IST). 3, 4 Although novel drugs targeting specific mechanisms have been suggested for treating GVHD, 5 the lack of standardized and validated response criteria remains a major obstacle in designing and interpreting clinical trials of treatment of chronic GVHD. 6 The provisional response criteria were proposed based on expert opinion in the 2005 National Institutes of Health (NIH) Consensus Conference. 6 Results from a recent prospective therapeutic trial showed that response defined according to these criteria correlated with survival in patients with steroid-refractory chronic GVHD, 7 but response did not correlate with survival in a multicenter, observational study of incident and prevalent cases of chronic GVHD. 8 We have proposed that the absence of systemic treatment change, nonrelapse mortality, and recurrent malignancy could be incorporated into a composite end point to evaluate results of treatment of chronic GVHD. 7 This composite failure-free survival (FFS) end point is more relevant than the individual components, because each of these events should be considered as failure in a clinical trial. The validity of the FFS end point has been evaluated after second-line systemic treatment of chronic GVHD 9 but not after initial systemic treatment.
The current study was designed to (1) determine the FFS rate after initial systemic treatment of patients with moderate or severe chronic GVHD according to NIH criteria, (2) elucidate risk factors associated with treatment failure, and (3) determine whether the dose of prednisone after 6 or 12 months of treatment is associated with long-term success in withdrawing all systemic treatment after resolution of chronic GVHD. Results after initial treatment were compared with those after second-line treatment, and success rates in this retrospective study were compared with those in a previous multicenter prospective study of initial systemic treatment.
Methods Patients and data collection
The study cohort included 400 consecutive relapse-free patients who received initial systemic treatment of moderate or severe chronic GVHD at the Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance between 2006 and 2010 after a first allogeneic transplantation. All patients were included regardless of the indication for transplantation, the conditioning regimen, graft source, donor relationship, or HLA matching.
Involved sites and types of treatment at onset of initial systemic treatment of chronic GVHD and treatment change after initial treatment were recorded prospectively via the Long-Term Follow-Up Program through medical records from our outpatient clinic and local clinics that provided primary care for patients. Services of the program include (1) evaluation of GVHD patients every 3 to 6 months and close communication with primary providers (;800 visits per year), (2) continuous care of patients requiring close monitoring more than once a month, and (3) telemedicine actively provided to patients and primary physicians by a dedicated team of experts. The values of platelet count, serum total bilirubin, and steroid doses, the NIH global score at onset of initial treatment, and steroid doses at 6 and 12 months after initial treatment were abstracted from medical records. All patients had given written consent allowing the use of medical records for research, and the Institutional Review Board of the Fred Hutchinson Cancer Research Center approved the study. The study was conducted in accordance with the Declaration of Helsinki.
Definitions
Chronic GVHD was defined according to the NIH consensus criteria. 10 Lung involvement was defined according to the NIH criteria for bronchiolitis obliterans.
11 Liver involvement was defined as an NIH liver score $1, where serum transaminase, alkaline phosphatase, and bilirubin concentrations were all taken into account. Treatment change was defined as any additional systemic treatment not used for initial treatment of chronic GVHD. Addition of systemic steroid for patients who were not initially treated with steroid was considered as treatment change. An increase in steroid dose in patients who were initially treated with steroid was not considered as treatment change, because temporarily increased steroid doses or resumption of steroid treatment are often necessary during the initial treatment of chronic GVHD. 12 FFS was defined by the absence of treatment change, nonrelapse mortality, and recurrent malignancy during initial systemic treatment. Recurrent malignancy was defined by hematologic relapse or any unplanned intervention to prevent progression of malignancy in patients with molecular, cytogenetic, flow cytometric, or any other evidence of malignant disease after 100 (25) CNI, calcineurin inhibitor; MMF, mycophenolate mofetil. *Other agents: extracorporeal photopheresis (n 5 11), methotrexate (n 5 5), rituximab (n 5 1), thalidomide (n 5 1), extracorporeal photopheresis and alemtuzumab (n 5 1), infliximab (n 5 1), and antithymocyte globulin (n 5 1).
†Other agents: extracorporeal photopheresis (n 5 1), rituximab (n 5 1), and thalidomide (n 5 1).
transplantation. An accelerated taper of IST due to evidence of recurrent disease was considered an unplanned intervention and categorized as recurrent malignancy. Permanent withdrawal of all systemic IST was defined as withdrawal of all systemic IST for $6 months without resuming IST.
12,13
Treatment of chronic GVHD At our center, chronic GVHD is generally treated by adding prednisone to any other immunosuppressive agents the patient is already taking.
14,15 Prednisone was most often initially administered at a dose of 1 mg/kg once daily for 2 weeks, and the dose was tapered during the subsequent 4 weeks to 1 mg/kg every other day as allowed by improvement in GVHD manifestations. After resolution of reversible manifestations of chronic GVHD, systemic treatment was gradually withdrawn. Decisions to initiate second-line treatment were made at the discretion of the attending physician.
Statistical analysis
Cumulative incidence estimates of recurrent malignancy, nonrelapse mortality, and treatment change as causes of failure during initial treatment were derived, treating each event as a competing risk for the other 2. 16 Permanent withdrawal of all IST during initial treatment after resolution of chronic GVHD was treated as a competing risk for all 3 types of failure. Rates of FFS were estimated by subtracting rates of total failures from 100%. Cox regression models were used to identify risk factors for failure. Factors having a likelihood ratio P # .05 for association with failure in univariate testing were included in a multivariate model. A backward elimination procedure was used to exclude risk factors until the P value of the likelihood ratio test for all remaining risk factors was #.05. Covariates at transplantation included patient age, disease risk, conditioning intensity, graft source, donor relation, HLA matching, and gender matching. Covariates at initial treatment included time from transplantation, involved sites, score of 3 in the gastrointestinal tract, liver, or lungs, number of involved sites, Karnofsky score, NIH global score, classic vs overlap subcategory, thrombocytopenia, hyperbilirubinemia, progressive onset, prior grade II to IV acute GVHD, steroid dose before initial treatment, and type and number of agents used for initial treatment. Prednisone-equivalent steroid doses of 0.3, 0.2, and 0.05 mg/kg daily at 6 months and 0.2, 0.05, and 0 mg/kg daily at 12 months were used as upper limits in evaluating the significance of incorporating prednisone dose in the FFS end point. These doses corresponded to the 75th, 50th, and 25th percentile doses at 6 and 12 months, respectively, among patients initially treated with regimens including steroids. The analysis was carried out as of August 2013.
Results

Characteristics of the study cohort
Patient characteristics are summarized in Table 1 . The median age of patients was 52 years (range, 1-79 years). Two hundred eighteen patients (54%) were prepared with high-dose conditioning regimens, and 332 (83%) received mobilized blood cell grafts.
GVHD characteristics at initial systemic treatment are summarized in Table 2 . The median time from transplantation to initial systemic treatment of chronic GVHD was 6.8 months (range, 2.6-58 months). The sites most frequently involved at the onset of initial systemic treatment were the mouth (91%) and skin (76%), followed by the liver (44%), gastrointestinal tract (40%), and eyes (28%). One hundred fifteen patients (29%) had involvement of $4 sites, 172 (43%) had a severe NIH global score, 335 (89%) had overlap chronic GVHD, 140 (35%) had a Karnofsky score ,80%, 105 (26%) had thrombocytopenia, 16 (4%) had hyperbilirubinemia, and 11 (3%) were receiving prednisone doses $1.0 mg/kg daily immediately before initial treatment. Initial treatment of chronic GVHD included prednisone with or without a calcineurin inhibitor in 203 patients (51%), prednisone with other combinations in 136 (34%), and treatment without prednisone in 61 patients (15%). Initial daily prednisone doses were $1.0 mg/kg in 196 patients (49%), $0.5 but ,1.0 mg/kg in 105 (26%), and ,0.5 mg/kg in 38 (10%). Sixty-one patients (15%) were not initially treated with steroids because they did not tolerate steroids or because GVHD could be adequately managed without steroids. One hundred patients (25%) were treated with regimens including $3 agents. The median follow-up among survivors was 53 months (range, 6-88 months) after initial treatment.
Outcomes after initial and second-line systemic treatment
The FFS rate after initial treatment was 68% (95% confidence interval [CI], 63-72%) at 6 months and 54% (95% CI, 48-58%) at 12 months ( Figure 1A ). Treatment change was the predominant category of treatment failure. Rates of nonrelapse mortality and recurrent malignancy as causes of treatment failure during initial For personal use only. on December 27, 2017. by guest www.bloodjournal.org From treatment were similar to each other and much lower than the rate of treatment change. The cumulative incidence of successful withdrawal of all IST after resolution of chronic GVHD during initial treatment was 13% (95% CI, 9-16%) at 24 months and reached 23% (95% CI, 19-28%) at 48 months. Treatment change occurred less frequently and later during initial treatment than during second-line treatment, whereas successful withdrawal of all IST occurred more frequently and earlier during initial treatment than during second-line treatment ( Figure 1A-B) . Across the observed 4-year time spans, rates of recurrent malignancy were slightly higher during initial treatment than during second-line treatment. Rates of nonrelapse mortality were similar between initial and second-line treatment.
Risk factors associated with treatment failure after initial systemic treatment
In univariate analysis (Table 3) , factors associated with risk of treatment failure included patient age, conditioning regimen, interval time from transplantation to initial systemic treatment, lower gastrointestinal involvement at initial treatment, score 3 in the gastrointestinal tract, liver, or lungs at initial treatment, and Karnofsky score at initial treatment. Initial steroid doses, type of initial treatment, and the number of agents used for initial treatment were not statistically associated with risk of treatment failure. No individual agent was associated with a statistically significant difference in the risk of treatment failure. In multivariate models, 4 risk factors remained statistically significant: onset of initial treatment of chronic GVHD within 12 months after transplantation, patient age $60 years, score 3 in the gastrointestinal tract, liver, or lungs, and Karnofsky score ,80% at initial treatment. All 4 risk factors were associated with increased risk of nonrelapse mortality. Karnofsky score ,80% and score 3 in the gastrointestinal tract, liver, or lungs at initial treatment were associated with increased risk of recurrent malignancy. None of the 4 risk factors was associated with treatment change.
Treatment failure rates according to risk groups
Forty-one patients (10%) had none of the 4 identified risk factors, 158 (40%) had 1 risk factor, 147 (37%) had 2 risk factors, 50 (13%) had 3 risk factors, and 4 (1%) had 4 risk factors. Rates of treatment failure were similar among groups with 0, 1, or 2 risk factors, and these 346 patients (86%) were categorized as standard risk. Rates of treatment failure were higher among 54 patients (14%) with 3 or 4 risk factors compared with standard-risk patients, and they were categorized as high risk. FFS rates in the standard and high-risk groups were 71% and 44%, respectively, at 6 months and 58% and 28%, respectively, at 12 months (Figure 2A ).
Long-term success in withdrawing all immunosuppressive treatment and survival according to failure-free status and steroid doses at 6 and 12 months after initial treatment
Among 357 and 319 patients without recurrent malignancy at 6 and 12 months after initial systemic treatment, respectively, treatment change before 6 or 12 months was associated with lower subsequent rates of success in withdrawing all IST during any line of treatment (P 5 .039 and , .001, respectively) ( Figure 3A,E) . Landmark analyses at 6 and 12 months did not show statistically significant differences in overall survival according to the presence or absence of prior treatment change (supplemental Figure 1A ,E, available on the Blood Web site). Among 227 patients initially treated with steroid and having FFS at 6 months, the median daily prednisone dose was 0.19 mg/kg (range, 0-1.6 mg/kg) at 6 months. Among 182 patients initially treated with steroid and having FFS at 12 months, the median daily prednisone dose was 0.049 mg/kg (range, 0-1.3 mg/kg) at 12 months. Steroid dose information was not available in 1 patient at 6 and 12 months, and this patient was excluded from the analysis. The cumulative incidence of IST withdrawal after resolution of chronic GVHD during initial treatment did not show statistically significant differences according to steroid thresholds at 6 months ( Figure 3B-D) . In contrast, the cumulative incidence of IST withdrawal was higher among patients taking prednisone-equivalent steroid doses #0.2 (n 5 141; 77.5%), #0.05 (n 5 92; 50.6%), or 0 mg/kg daily (n 5 73; 40.1%) at 12 months compared with those taking, respectively, higher doses (P 5 .017, , .001 and , .001, respectively) ( Figure 3F-H) . The cumulative incidence of IST withdrawal at 48 months after initial treatment was 50% for those with doses #0.2 mg/kg daily, 58% for those with doses #0.05 mg/kg daily, and 56% for those who were taking no prednisone at 12 months. Subsequent overall survival was slightly better among patients taking doses #0.3 or #0.2 mg/kg/day at 6 months compared with those taking respectively higher doses (supplemental Figure 1B-C) . Differences were not statistically significant according to steroid doses at 12 months (supplemental Figure 1F-H) .
Success rates at 12 months according to risk groups Table 4 summarizes success rates with and without steroid dose limits at 12 months according to risk groups. The FFS rate was 0.54 at 12 months among all patients. As stated above, proportions of failure-free patients who met the dose limits of prednisone #0.2, #0.05, and 0 mg/kg daily were 77.5%, 50.6%, and 40.1% at 12 months, respectively. When these dose limits were each incorporated as an additional criterion by multiplication, success rates decreased to 0.42, 0.27, and 0.22, respectively. Patterns were similar in each of the individual risk groups.
Comparison of FFS rates between the current study and a previously performed multicenter prospective trial FFS rates were calculated using the dataset of a previous multicenter prospective trial of initial systemic treatment. 12 Forty patients included in the current study were excluded from the prospective dataset so that no patients overlapped between the cohorts. Among 111 patients in the multicenter prospective study, 109 were categorized as standard risk. FFS rates were closely similar to those for the standard-risk patients in the current study ( Figure 2B ). Only 2 patients in the prospective study were categorized as high risk, in part because hospitalized patients and those with bronchiolitis obliterans were excluded. These 2 patients had early treatment failure at 15 and 19 days after initial treatment, respectively. Success rates incorporating prednisone doses were not compared, because information regarding prednisone doses at 12 months was available for only a small proportion of patients in the prospective trial.
Discussion
This study provides important benchmarks for designing future clinical trials. First, we defined FFS as a novel composite end point for clinical trials and characterized the FFS outcomes after initial systemic treatment of moderate or severe chronic GVHD. Second, with treatment change added to nonrelapse mortality and recurrent malignancy in the composite end point, the event rate increased substantially, increasing the opportunity to demonstrate improved results in future studies. Third, we identified 4 objective risk factors associated with treatment failure and defined a group of patients with high risk of treatment failure. Fourth, we found that lower steroid doses among patients with FFS at 12 months were associated with successful withdrawal of all systemic treatment after resolution of chronic GVHD, an unequivocal long-term clinical benefit. Finally, we report success rates accounting both for risk groups and steroid dose limits at 12 months to make the end point more meaningful and to enhance the clinical benefit associated with the end point.
This study included consecutive contemporary patients with moderate or severe chronic GVHD at our center to approximate the characteristics of patients who could be enrolled in future clinical trials of initial treatment of chronic GVHD. Notably, treatment failure was not associated with initial prednisone dose or type of initial treatment, and an independent cohort from a multicenter prospective study showed similar success rates. Thus, the results support the use of FFS as a robust benchmark that could be used for designing and interpreting future phase 2 trials of initial treatment of chronic GVHD.
Early onset of chronic GVHD, low Karnofsky performance, older patient age, and a score of 3 in the gastrointestinal tract, liver, or lungs were the risk factors associated with increased risk of treatment failure in this study. These risk factors have been associated with mortality after initial treatment. 3, 15, 17, 18 Because these risk factors are objective and easy to evaluate at any transplant center, they are suitable for use in multicenter studies. In a multicenter observational study including both incident and prevalent cases, 19 the risk of mortality was higher in patients with overlap subtype than in those with classic subtype. The proportion of patients with overlap manifestations was 89% among incident cases in the multicenter study, 19 identical to the proportion from our study. In comparing the results between initial and second-line treatment, major differences in outcomes included less frequent treatment change and more frequent and earlier withdrawal of all IST after initial treatment than after secondline treatment, suggesting that chronic GVHD is more responsive during initial treatment as compared with second-line treatment.
In the absence of standardized and validated criteria for measuring treatment response, steroid doses at the time of end point assessment might increase the clinical benefit associated with the end point. Unlike second-line treatment, incorporation of an upper limit of steroid dose in the 6-month FFS end point did not show statistically significant association with successful withdrawal of IST. 9 This difference could be explained by the possibility that evaluation after 6 months of initial treatment is too short to predict long-term outcomes. Some manifestations of chronic GVHD such as sclerosis improve very slowly, and assessment of these manifestations at time points later than 6 months after treatment has been recommended. 20, 21 Response at 6 months did not correlate with subsequent development of tolerance, 22 and conflicting results have been reported for the association of response at 6 months with subsequent mortality. 7, 8 Although assessment at 6 months is "quick and convenient," our results support the use of an assessment that incorporates prednisone doses after 12 months of initial treatment. Success with this end point in a phase 2 study would increase the probability that subsequent phase 3 trials will demonstrate differences in successful withdrawal of all systemic treatment as a longterm goal demonstrating unequivocal clinical benefit.
The use of FFS as a primary end point in chronic GVHD treatment trials has several caveats. First, the FFS end point does not give any direct information about changes in GVHD-related symptoms, activity, damage, or disability. Studies using FFS as the primary end point should evaluate all of these measures as secondary end points. Second, results with this end point require careful interpretation in nonblinded trials. The composite end point includes objective components, including death, recurrent malignancy, and the fact of treatment change, but decisions to change treatment are controlled by providers and can be motivated by a variety of factors, including the presence of chronic GVHD manifestations that are progressing, persisting without improvement, or improving more slowly than desired. Changes may also be motivated by toxicity, inconvenience, financial burden, or the availability of a newer alternative that is more attractive to the patient or physician. In nonblinded clinical trials, intentionally delayed treatment changes could increase the risk of false-positive results, whereas premature treatment changes could increase the risk of falsenegative results. Controlled designs with blinding should be used whenever feasible to mitigate these risks when FFS is used as the primary end point. Guidelines for tapering steroid doses and clear definitions of appropriate indications for treatment change could enhance the objectivity of this end point. Lastly, the benchmark rates from this study might not apply to pediatric patients or to patients with nonmalignant diseases, because the study cohort included few such patients.
To date, 6 phase 3 randomized trials have explored whether initial therapy was improved by adding an immunosuppressive agent to conventional corticosteroid treatment, 12, 18, [23] [24] [25] [26] but no study showed superiority of the investigational arm. Therefore, robust and efficient phase 2 studies are needed to identify promising drugs that could be tested in phase 3 studies. FFS serves as a potentially useful basis for designing such trials and for interpreting results of initial treatment of chronic GVHD. Incorporation of a steroid dose limit at 12 months after initial treatment as an additional criterion would increase the degree of clinical benefit associated with FFS. In the future, it should be possible to replace FFS with a standardized and validated measure of response as the primary end point to measure clinical benefit in a more direct way.
